Keymed Biosciences Inc.
Keymed Biosciences Inc., a biotechnology company, engages in the research and development of biological therapies for the treatment of autoimmunity and oncology diseases. Its lead product candidate is CM310 for the treatment of moderate to severe atopic …
Biotechnology
CN, Chengdu [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
1
Financial Health
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Current Ratio | 0.00 | 9.36 | 9.36 | |
| Debt/Assets | n.A. | n.A. | n.A. | |
| Debt/Equity | n.A. | n.A. | n.A. | |
| Net Debt/EBITDA | 10.14 | 2.14 | 1.94 | |
| Naive Interpretation | member | |||
2
Per Share
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Book Value | 0.00 | 11.45 | 11.45 | |
| Cash | 6.85 | 10.42 | 9.75 | |
| Capex | 0.00 | -0.15 | -0.15 | |
| Free Cash Flow | 0.00 | -0.81 | -0.81 | |
| Revenue | 0.00 | 0.05 | 0.05 | |
| Naive Interpretation | member | |||
3
Profitability
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Gross Margin | 0.00 | 0.19 | 0.19 | |
| Operating Margin | 0.00 | -16.20 | -16.20 | |
| ROA | 0.00 | -0.05 | -0.05 | |
| ROE | 0.00 | -0.07 | -0.07 | |
| ROIC | -1.17 | -0.06 | -0.06 | |
| Naive Interpretation | member | |||
4
Valuation
The "Valuation Entry" for the Focus of 2162.HK is permitted for members.
5
Growth
The "Growth Entry" for the Focus of 2162.HK is permitted for members.
6
Leverage & Liquidity